Genoway

Genoway LT Debt/Equity

The Long-Term Debt to Equity Ratio of Genoway (ALGEN.PA) as of Oct 21, 2026 is 0.50. In the previous year, Long-Term Debt to Equity Ratio was 0.22 — a change of 124.27% (higher).

LT Debt/Equity

0.50

YoY

124.27%

Last updated:

Long-Term Debt to Equity Ratio of Genoway is 2025 0.50 . Long-Term Debt to Equity Ratio of Genoway was 2024 0.22 . It decreases by 124.27% higher compared to the previous year.

The Genoway LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.55 EUR
Jan 1, 2019
0.77 EUR
Jan 1, 2020
1.11 EUR
Jan 1, 2021
0.61 EUR
Jan 1, 2022
0.45 EUR
Jan 1, 2023
0.32 EUR
Jan 1, 2024
0.22 EUR
Jan 1, 2025
0.50 EUR
The Genoway LT Debt/Equity history
YEARLT Debt/EquityYoY
0.50+124.27%
0.22-29.83%
0.32-28.71%
0.45-27.11%
0.61-45.10%
1.11+44.66%
0.77+40.78%
0.55+5.31%
0.52—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genoway stock

Long-Term Debt to Equity Ratio of Genoway is 0.50 in 2025.

Long-Term Debt to Equity Ratio of Genoway changed from 0.22 to 0.50, representing a 124.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Genoway since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Genoway with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genoway

All Key Metrics — Genoway